← SynDRA
PHA-665752
SynDRA canonical compound SYN0011441 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | MET |
|---|
| Mechanism of action | c-Met inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- PAK4
- PIK3C2B
- PI4KB
- PHKG2
- PHKG1
- PDPK1
- PDGFRB
- PDGFRA
- PAK6
- PAK5
- PAK3
- PIK3CA
- PAK2
- PAK1
- OXSR1
- NUAK2
- NUAK1
- NTRK3
- NTRK2
- NTRK1
- NLK
- PIK3C2G
- PIK3CB
- PRKCH
- PKN2
- PRKCD
- PRKACB
- PRKACA
- PRKAA2
- PRKAA1
- PLK4
- PLK3
- PLK2
- PLK1
- PKN1
- PIK3CD
- PKMYT1
- PIP5K1C
- PIP5K1A
Cross-references
Synonyms
- PHA 665752
- PHA665752
- TCMDC-125885
- UNII-0VXU5T5R3J
- (2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE
- 0VXU5T5R3J
- CHEMBL450786
- CHEBI:90197
- (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one
- PHA-665752 hydrate
- RefChem:1050350
- DTXCID40119761
- C32H34Cl2N4O4S
- OYONTEXKYJZFHA-SSHUPFPWSA-N
- MFCD07772270
- SCHEMBL93654
- GTPL5700
- orb1301049
- SCHEMBL29376386
- EX-A019
- GLXC-06072
- HMS3269N19
- HMS3413B20
- HMS3677B20
- BDBM50242737
- MFCD18632554
- NSC748798
- NSC766271
- PHA 665752 [WHO-DD]
- AKOS015896678
- CCG-264805
- CS-0137
- EBC-224069
- FP71590
- NSC-748798
- NSC-766271
- SDCCGSBI-0654452.P001
- PHA-665752?
- NCGC00346642-11
Look up PHA-665752 in the interactive SynDRA portal →